It is found that hyperlipidemia is responsible for triggering cardiovascular risks. But, there are restricted options for patients who are either intolerant to statin therapy or develop cardiovascular risks in spite of tolerated statin therapy.

PCSK9 inhibitors mark the class of emerging lipid-lowering molecules as it blocks the PCSK9 and lowers the LDL cholesterol. This exclusive commentary illustrates the highlighting aspects of PCSK9 inhibitors for hyperlipidemia.